Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (0HI3.L) Financial Performance & Income Statement Overview
Analyze Arrowhead Pharmaceuticals, Inc. (0HI3.L) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Arrowhead Pharmaceuticals, Inc. (0HI3.L) Income Statement & Financial Overview
Analyze Arrowhead Pharmaceuticals, Inc.’s 0HI3.L earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $542.71M | $2.50M | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $542.71M | $2.50M | $0.00 | $0.00 |
| Gross Profit Ratio | $1.00 | $1.00 | $0.00 | $0.00 |
| R&D Expenses | $133.10M | $137.002M | $135.83M | $152.43M |
| SG&A Expenses | $27.89M | $26.40M | $25.79M | $23.20M |
| Operating Expenses | $161.51M | $163.91M | $162.20M | $176.14M |
| Total Costs & Expenses | $161.51M | $163.91M | $162.20M | $176.14M |
| Interest Income | $9.62M | $7.60M | $7.17M | $6.50M |
| Interest Expense | $21.64M | $21.65M | $14.65M | $5.09M |
| Depreciation & Amortization | $6.08M | $5.24M | $5.03M | $4.78M |
| EBITDA | $397.34M | -$148.23M | -$153.13M | -$164.10M |
| EBITDA Ratio | $0.73 | -$59.29 | $0.00 | $0.00 |
| Operating Income | $381.20M | -$161.41M | -$162.20M | -$176.14M |
| Operating Income Ratio | $0.70 | -$64.56 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | -$11.59M | -$13.70M | -$10.60M | $2.16M |
| Income Before Tax | $369.62M | -$175.12M | -$172.80M | -$173.98M |
| Income Before Tax Ratio | $0.68 | -$70.05 | $0.00 | $0.00 |
| Income Tax Expense | $1.75M | $103000.00 | $546000.00 | $0.00 |
| Net Income | $370.44M | -$173.09M | -$170.54M | -$170.79M |
| Net Income Ratio | $0.68 | -$69.23 | $0.00 | $0.00 |
| EPS | $2.78 | -$1.39 | -$1.40 | -$1.38 |
| Diluted EPS | $2.75 | -$1.39 | -$1.40 | -$1.38 |
| Weighted Avg Shares Outstanding | $133.36M | $124.85M | $121.99M | $124.20M |
| Weighted Avg Shares Outstanding (Diluted) | $134.48M | $124.85M | $121.99M | $124.20M |
Over the last four quarters, Arrowhead Pharmaceuticals, Inc.'s revenue moved from $0.00 in Q3 2024 to $542.71M in Q2 2025. Operating income in Q2 2025 was $381.20M, with a strong operating margin of 70%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Arrowhead Pharmaceuticals, Inc. remained robust at $397.34M, reflecting operational efficiency. Net income rose to $370.44M, with an EPS of $2.78. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan